Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정송미 | * |
dc.date.accessioned | 2019-01-24T16:30:04Z | - |
dc.date.available | 2019-01-24T16:30:04Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 0360-3016 | * |
dc.identifier.other | OAK-24188 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/248198 | - |
dc.description.abstract | Purpose: The role of adjuvant chemotherapy after preoperative chemoradiation therapy (CRT) and curative surgery in rectal cancer has yet to be definitely determined. We performed a retrospective and multicenter study to evaluate whether adjuvant chemotherapy (AC) could reduce recurrence and improve survival in locally advanced rectal cancer. Methods and Materials: We analyzed data from 8 tertiary institutions for 1442 patients with rectal cancer who underwent preoperative CRT and total mesorectal excision. Patients were classified into 2 groups: the AC group (patients who received chemotherapy after surgery) and the observation group (those who did not receive chemotherapy after surgery). Propensity-score matching was used to assess the exact role of AC. The AC group was then subdivided to investigate the impact of adding oxaliplatin to 5-fluorouracil (5-FU). Group 1 was treated with 5-FU/folinic acid or capecitabine without oxaliplatin, and group 2 received 5-FU/folinic acid or capecitabine with oxaliplatin. Results: The 3-year relapse-free survival rates in the AC and observation groups were 85.9% and 84.3%, respectively (P =.532). The 3-year overall survival rates in the AC and observation groups were 94.9% and 89.9%, respectively (P =.123). The rates of locoregional recurrence (2.2% vs 3.2%, P =.294) and distant metastasis (12.4% vs 12.9%, P =.927) at 3 years were not significantly different between the two groups. The 3-year relapse-free survival rates of group 1 and group 2 were 71.5% and 74.8%, respectively (P =.426). The 3-year overall survival rates of group 1 and group 2 were 89.9% and 96.5%, respectively (P =.102). Conclusions: This multicenter study found insufficient evidence to support the use of 5-FU–based AC after preoperative CRT and curative surgery in rectal cancer. © 2018 Elsevier Inc. | * |
dc.language | English | * |
dc.publisher | Elsevier Inc. | * |
dc.title | Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 103 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 438 | * |
dc.relation.lastpage | 448 | * |
dc.relation.journaltitle | International Journal of Radiation Oncology Biology Physics | * |
dc.identifier.doi | 10.1016/j.ijrobp.2018.09.016 | * |
dc.identifier.wosid | WOS:000455220100022 | * |
dc.identifier.scopusid | 2-s2.0-85059564530 | * |
dc.author.google | Chung M.J. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Kim S.H. | * |
dc.author.google | Song J.H. | * |
dc.author.google | Jeong S. | * |
dc.author.google | Yu M. | * |
dc.author.google | Nam T.K. | * |
dc.author.google | Jeong J.U. | * |
dc.author.google | Jang H.S. | * |
dc.contributor.scopusid | 정송미(55756694500) | * |
dc.date.modifydate | 20240318140240 | * |